IRVINE, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Gala Global, Inc. (OTCBB:GLAG) announces its filing a name change to Gala Pharmaceuticals Inc. The name change more closely aligns Gala Pharmaceuticals Inc., (GPI) to its target markets and changing business model.
GPI will offer plant genomic research, genomic breeding technology, specialty genomic products and laboratory services to agricultural and pharmaceutical sectors. This strategy will align GPI with the emerging needs of biopharmaceutical and pharmaceutical services markets. The Company’s business strategy entails the use of proprietary equipment and techniques to ensure the genetic fingerprint of each plant is identical and is cultivated in a controlled environment, significantly reducing the variability of each plants and enhance the desired yield. GPI will provide cGMP (Good Manufacturing Practices) production of Active Pharmaceutical Ingredients (API) for use in clinical trials required to make efficacy claims for varying medical indications.
GPI has acquired the services of top genetic, biological and pharmaceutical scientists to create robust, repeatable processes needed to accomplish Gala Pharmaceuticals Inc.’s business strategy of cGMP and API.
Gala Pharmaceuticals Inc., has contracted services of Mark Livingston
Mr. Livingston has operated a pharmaceutical manufacturing firm in San Diego, CA for over 9 years. Mr. Livingston provides leadership to Gala Pharmaceuticals Inc. and assist in setting the strategic direction of the company and instilling a culture of quality and continuous improvement. He is experienced in operations, finance, strategic planning, start-up companies, company turnarounds, management information systems and planning for the succession of closely held businesses.
Gala Pharmaceuticals Inc., has contracted the services of Nayaz Ahmed, PhD, RAC (US, EU), CQA, Director of Analytical Services & Product Development
Dr. Ahmed is a quality and pharmaceutical development scientist, has over 25 years of industry experience in R&D, regulatory compliance and quality control. He creatively resolves CMC and outstanding quality issues with firm knowledge of FDA, EU, ISO and ICH standards related to pharmaceuticals, biologicals and medical devices. As a PI, Dr. Ahmed received a SBIR award from National Institute of Health for developing “Organosilicon Compounds for Cancer Prevention” and served as a member of NIH/NCI peer review committee of the National Cooperative Drug Discovery Group for Cancer. At Gala Pharmaceuticals Inc., Dr. Ahmed will provide oversight to product development and to maintain robust comprehensive quality and compliance systems to meet applicable current State, Federal and International regulations and standards.
Gala Pharmaceuticals Inc., has contracted the services of Arshad Chaudry, Director of QC, Microbiology and Validation
Mr. Chaudry is a senior scientist experienced in commercial and R&D pharmaceutical microbiology and quality system validations. He has over 25 years of experience as a microbiologist, and is a consultant to GPI’s management team. Mr. Chaudry has extensive experience with regulatory agencies and will assist GPI in its FDA and ISO inspections.
Mr. Chaudry will play a key role in managing GPI’s manufacturing operations and the implementation of cGMP -standards to maintain its compliance with regulatory agencies.
Gala Pharmaceuticals Inc., has contracted services of Peter Um
Peter Um is a Molecular Biologist, Microbiologist, and Chemist with over 10 years of biomedical and applied biotechnology research experience. He received his Bachelors of Science in Molecular Biology with a Minor in Chemistry from Westminster College. He also received his Masters in Biotechnology from Johns Hopkins University. Peter has a diverse scientific background and brings a wealth of experience and knowledge regarding biotechnology to Gala Pharmaceuticals.
The Company anticipates the installation and operation of a state of the art analytical laboratory and genetic engineering facility in San Diego County in Q1-2018.
To be added to Gala Global’s investor lists, please contact Bill Miller at 844-565-5665 or via email at bmiller@irpartnersinc.com.
Or like our Facebook page @
https://www.facebook.com/gala-pharmaceuticals-147596665868456
About Gala Pharmaceuticals Inc.
Gala Pharmaceuticals Inc., Irvine, Calif., is a publicly-traded startup company specializing in biotechnology and biopharmaceuticals. Gala Pharmaceuticals Inc., uses proprietary equipment and techniques in the field of plant biotechnology and biopharmaceutical product development. Gala Pharmaceuticals professional services group provides operational services and technologies that drive efficiencies in the market. Gala Pharmaceuticals has industry-leading expertise helping customers make the most of their potential in an emerging market. Gala Pharmaceuticals website: www.galapharmaceuticals.com.
Disclaimer: The Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcement.
Contact
Maqsood Rehman, CEO
Gala Pharmaceuticals , Inc.
maqsood@galapharmaceuticals.com
(657) 215-5742